NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









AlphaGen Therapeutics

AlphaGen Therapeutics

Private
ShanghaiHealthcare & Life Scienceshttps://www.alphagentx.com/

Last Round

Series A

Aug 7, 2025

Momentum

Top 25%

of companies Caplight tracks

Company Overview

AlphaGen Therapeutics is a biopharmaceutical company that focuses on the discovery, development, manufacturing, and commercialization of innovative targeted radioligand therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

targeted radioligand therapyRLTalpha-emitting radiopharmaceuticalsLead-212Pb-212radiopharmaceutical supply chaintargeted alpha therapyisotope isolationoncology therapeuticscancer treatmentprecision medicinetheranosticsbiopharmaceuticalclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AlphaGen Therapeutics Comparables

Compare AlphaGen Therapeutics with similar companies based on industry and business-model similarity.

AlphaGen Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
C-Ray Therapeutics
88%
AdvanCell
85%
ARTBIO
85%

AlphaGen Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 7, 2025
SeedOct 18, 2023

Key People

Founding team and executive leadership

Tao Bob Wu

Chief Technology Officer

Executive Team

Zhifan Hu

Acting COO, Board Director

Executive Team

AlphaGen Therapeutics Investors

Notable investors and investment history

AlphaGen Therapeutics investors
InvestorRounds
Eight Roads VenturesSeed
Eight Roads Ventures ChinaSeed
F-Prime CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 21, 2026

    Two next-generation alpha therapies are in preclinical studies.

  • Apr 21, 2026

    Presenting preclinical studies at AACR 2026.

AlphaGen Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AlphaGen Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AlphaGen Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range8
Year Founded2022
Last FundingAug 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.